B4GALT5 inhibits CD8 + T-cell response by downregulating MHC-I level through ERAD pathway in PDAC
Journal for ImmunoTherapy of Cancer · 2025-05 · 13 (5) · e010908
DOI: 10.1136/jitc-2024-010908 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 02.05.2025. Verfasst von Xin Xing und 13 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Fengxian District Central Hospital, School of Medicine, Anhui University of Science and Technology, Shanghai, China. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Galactosyltransferases, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: EPA, Scientific Research Foundation of SUMHS, Innovative Research Team of High-level Local University in Shanghai.
Abstract (Originalsprache)
Background
Immune evasion is a crucial event in the progression of pancreatic ductal adenocarcinoma (PDAC). The identification of new immunotherapeutic targets may provide a promising platform for advancing PDAC treatment. This study aims to investigate the role of beta-1,4-galactosyltransferase-5 (B4GALT5) in immune evasion by pancreatic cancer cells and evaluate its potential as an immunotherapeutic target.
Methods
We conducted a comprehensive analysis using RNA sequencing data and tissue microarrays from patients with PDAC to investigate the association between B4GALT5 expression and patient prognosis. Using animal models, we further explored the impact of B4GALT5 on the quantity and activity of tumor-infiltrating CD8 + T cells. RNA sequencing and co-immunoprecipitation were used to explore the mechanism by which B4GALT5 regulates major histocompatibility complex (MHC-I) levels.
Results
Our study demonstrates that high expression of B4GALT5 in tumor cells is significantly associated with poor prognosis in patients with PDAC and reduced cytotoxic activity of tumor-infiltrating CD8 + T cells. Specifically, B4GALT5 suppresses MHC-I expression in tumor cells through the endoplasmic reticulum-associated degradation pathway, enabling them to evade immune surveillance by CD8 + T cells.
Conclusions
B4GALT5 impairs CD8 + T-cell recognition of tumor cells by regulating MHC-I levels, thereby promoting immune evasion. This makes B4GALT5 a highly promising immunotherapeutic target for improving the poor prognosis of patients with PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Fengxian District Central Hospital, School of Medicine, Anhui University of Science and Technology, Shanghai, China.
- Shanghai University of Medicine and Health Sciences Affiliated Sixth People's Hospital South Campus, Shanghai, China.
- State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- The First Hospital of Jilin University, Changchun, Jilin, China.
- Department of Gastrointestinal Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China xlzhang@shsci.org yangyang201298@163.com xmyang@shsci.org huoyanmiao@126.com.
Förderung
- EPA
- Scientific Research Foundation of SUMHS
- Innovative Research Team of High-level Local University in Shanghai
- Key Medical Disciplines of Shanghai Municipal Health Commission
- Natural Science Foundation of Shanghai
Zitieren
APA
Xing, X., Yin, S. Q., Li, X. Q., Li, H., Ma, H. T., Tulamaiti, A., Xiao, S. Y., Liu, Y. T., Zhang, H., Zhang, Z., Huo, Y. M., Yang, X. M., Yang, Y., & Zhang, X. L. (2025). B4GALT5 inhibits CD8 + T-cell response by downregulating MHC-I level through ERAD pathway in PDAC. Journal for ImmunoTherapy of Cancer, 13(5), e010908. https://doi.org/10.1136/jitc-2024-010908
Vancouver
Xing X, Yin SQ, Li XQ, Li H, Ma HT, Tulamaiti A, et al. B4GALT5 inhibits CD8 + T-cell response by downregulating MHC-I level through ERAD pathway in PDAC. Journal for ImmunoTherapy of Cancer. 2025;13(5):e010908. doi:10.1136/jitc-2024-010908
BibTeX
@article{Xing2025,
author = {Xing, Xin and Yin, Shi-Qi and Li, Xia-Qing and Li, Hui and Ma, Hong-Tai and Tulamaiti, Aziguli and Xiao, Shu-Yu and Liu, Yu-Tong and Zhang, Hao and Zhang, Zhigang and Huo, Yan-Miao and Yang, Xiao-Mei and Yang, Yan and Zhang, Xue-Li},
title = {B4GALT5 inhibits CD8 + T-cell response by downregulating MHC-I level through ERAD pathway in PDAC},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
volume = {13},
number = {5},
pages = {e010908},
doi = {10.1136/jitc-2024-010908}
}
EUVIMED